Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.46 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.41 |
| ▸ | TUBB | P07437 | 3/20 | 0.41 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.41 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.41 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.41 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.41 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.41 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.41 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.41 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.41 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.41 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.41 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.41 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.41 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.41 |
| ▸ | BRD4 | O60885 | 3/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL559928 | 1.00 | MTNR1A (0.46) | MTNR1ATUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL560148 | 0.81 | MTNR1A (0.46) | MTNR1ASLC6A3ALDH1A1PDE4APDE4B | |
| SCHEMBL560158 | 0.80 | MTNR1A (0.44) | MTNR1ACREBBPSLC6A3MAPTALDH1A1 | |
| SCHEMBL559693 | 0.76 | MTNR1A (0.50) | MTNR1ABRD4PIM1PIM2SLC6A3 | |
| SCHEMBL559949 | 0.73 | MTNR1A (0.47) | MTNR1ASLC6A3ALDH1A1PDE4APDE4B | |
| SCHEMBL20177704 | 0.73 | MTNR1A (0.48) | MTNR1AALDH1A1PDE4APDE4BPDE4C | |
| SCHEMBL560175 | 0.73 | MTNR1A (0.48) | MTNR1ASLC6A3ALDH1A1HTTPDE4A | |
| SCHEMBL559712 | 0.73 | MTNR1A (0.48) | MTNR1AALDH1A1PDE4APDE4BPDE4C | |
| SCHEMBL559629 | 0.73 | MTNR1A (0.48) | MTNR1ASLC6A3ALDH1A1PDE4APDE4B | |
| SCHEMBL560228 | 0.72 | MTNR1A (0.46) | MTNR1ANPC1MAPTRAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344028-B2 | Gamma-amino-butyric acid derivatives as GABAB receptor ligands | XENOPORT, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| EP-2419401-A2 | GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAb RECEPTOR LIGANDS | XenoPort, Inc. (US) | 2012-02-22 | — | — | EP | disclosed |
| US-20120035139-A9 | GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS | XENOPORT, INC. | 2012-02-09 | — | — | US | disclosed |
| US-20100267676-A1 | GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS | XENOPORT, INC. | 2010-10-21 | — | — | US | disclosed |
| WO-2010120370-A2 | GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS | XENOPORT, INC. (US) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267676-A1 | GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS | GABRB2, GABRB1, GABRB3 | MTNR1A 394/4885TUBB4A 291/4885TUBB 122/4885 |
| US-20120035139-A9 | GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS | GABRB2, GABRB1, GABRB3 | MTNR1A 394/4885TUBB4A 291/4885TUBB 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.